Skip to content

Study · Measured the body's own peptide · 2011

1 result

Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.

He J, Whelan SA, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP, Chang HR

International journal of proteomics24 Oct 2011Cited by 28 (Europe PMC)

PMID22110952 (opens in a new tab)PMCIDPMC3202144 (opens in a new tab)DOI10.1155/2011/896476 (opens in a new tab)PepBankPUB-22110952
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Protein-based markers that classify tumor subtypes and predict therapeutic response would be clinically useful in guiding patient treatment. We investigated the LC-MS/MS-identified protein biosignatures in 39 baseline breast cancer specimens including 28 HER2-positive and 11 triple-negative (TNBC) tumors. Twenty proteins were found to correctly classify all HER2 positive and 7 of the 11 TNBC tumors. Among them, galectin-3-binding protein and ALDH1A1 were found preferentially elevated in TNBC, whereas CK19, transferrin, transketolase, and thymosin β4 and β10 were elevated in HER2-positive cancers. In addition, several proteins such as enolase, vimentin, peroxiredoxin 5, Hsp 70, periostin precursor, RhoA, cathepsin D preproprotein, and annexin 1 were found to be associated with the tumor responses to treatment within each subtype. The MS-based proteomic findings appear promising in guiding tumor classification and predicting response. When sufficiently validated, some of these candidate protein markers could have great potential in improving breast cancer treatment.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In breast cancer specimens, thymosin β4 was elevated in HER2-positive tumours compared with triple-negative tumours.

    In plain wordsIn breast tumour samples, the body's own thymosin beta‑4 was higher in HER2-positive tumours than in triple-negative tumours.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseThymosin β4 level in HER2-positive versus triple-negative breast cancer
    Study

    n = 39

    Comparator
    Triple-negative breast cancer
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    CK19, transferrin, transketolase, and thymosin β4 and β10 were elevated in HER2-positive cancers.
    1 context sentence
    Summary · context
    We investigated the LC-MS/MS-identified protein biosignatures in 39 baseline breast cancer specimens including 28 HER2-positive and 11 triple-negative (TNBC) tumors.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.